Novo Nordisk A/S (NVO) Financials
NVO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 46.6 billion | 30.8 billion |
| 2023-09-30 | 42.6 billion | 29.4 billion |
| 2023-06-30 | 41.0 billion | 27.8 billion |
| 2023-03-31 | 36.6 billion | 24.9 billion |
NVO Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | -1.0 billion | 3.5 billion |
| 2023-09-30 | 4.3 billion | -464.8 million |
| 2023-06-30 | 3.1 billion | -663.8 million |
| 2023-03-31 | 3.7 billion | ? |
NVO Net Income
| Date | Net Income |
|---|---|
| 2023-12-31 | 3.3 billion |
| 2023-09-30 | 3.2 billion |
| 2023-06-30 | 2.8 billion |
| 2023-03-31 | 2.9 billion |
NVO Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 4.5 billion | - | 847.7 million |
| 2023-09-30 | 6.7 billion | 2.8 billion | - |
| 2023-06-30 | 5.3 billion | 2.8 billion | - |
| 2023-03-31 | 4.1 billion | 3.6 billion | - |
NVO Shares Outstanding
NVO Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 2.4 billion | 1.5 billion | 215.6 million | 2.5 billion |
| 2023-09-30 | 1.5 billion | 1.2 billion | 178.1 million | 1.8 billion |
| 2023-06-30 | 1.0 billion | 1.0 billion | 156.6 million | 2.1 billion |
| 2023-03-31 | 702.9 million | 985.0 million | 156.8 million | 1.8 billion |
NVO Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 9.8 billion | 1.5 billion |
| 2023-09-30 | 8.3 billion | 1.4 billion |
| 2023-06-30 | 7.9 billion | 1.1 billion |
| 2023-03-31 | 7.8 billion | 1.2 billion |
NVO
Price: $127.73
Dividend Yield: 0.07%
Forward Dividend Yield: 1.03%
Payout Ratio: 49.35%
Dividend Per Share: 1.33 USD
Earnings Per Share: 2.68 USD
P/E Ratio: 44.61
Exchange: NYQ
Sector: Healthcare
Industry: Biotechnology
Volume: 1.1 million
Ebitda: 1.9 billionMarket Capitalization: 564.6 billion
Average Dividend Frequency: 1
Years Paying Dividends: 43
DGR3: 12.61%
DGR5: 6.80%
DGR10: 30.00%
DGR20: 30.00%